Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo.

[1]  J. Holst,et al.  Truncated GLP-1 (proglucagon 78–107-amide) inhibits gastric and pancreatic functions in man , 1993, Digestive Diseases and Sciences.

[2]  J. Holst,et al.  Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in Type 2 (non-insulin-dependent) diabetic patients , 1993, Diabetologia.

[3]  M. Aubert,et al.  Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. , 2002, Diabetes.

[4]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[5]  R. Pederson,et al.  Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. , 2002, Diabetes.

[6]  J. Holst,et al.  GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. , 2002, American journal of physiology. Endocrinology and metabolism.

[7]  P. Chailler,et al.  Laminins and TGF-beta maintain cell polarity and functionality of human gastric glandular epithelium. , 2002, American journal of physiology. Cell physiology.

[8]  J. Holst,et al.  Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study , 2002, The Lancet.

[9]  T. Hughes,et al.  Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. , 2002, The Journal of endocrinology.

[10]  P. Damsbo,et al.  Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment. , 2001, Diabetes care.

[11]  D. Marguet,et al.  Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[12]  A. Astrup,et al.  The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans , 2000, International Journal of Obesity.

[13]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[14]  J. Holst,et al.  Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7–36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats , 1999, Diabetologia.

[15]  A. Edvell,et al.  Initiation of Increased Pancreatic Islet Growth in Young Normoglycemic Mice (Umeå +/?). , 1999, Endocrinology.

[16]  M. Byrne,et al.  Glucagon-Like Peptide 1 Improves the Ability of the β-Cell to Sense and Respond to Glucose in Subjects With Impaired Glucose Tolerance , 1998, Diabetes.

[17]  R. Pederson,et al.  Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide , 1998, Diabetes.

[18]  J. Holst,et al.  Dipeptidyl peptidase IV inhibition potentiates the insulinotropic effect of glucagon-like peptide 1 in the anesthetized pig. , 1998, Diabetes.

[19]  B. Göke,et al.  Endoproteolysis of Glucagon-like Peptide (GLP)-1(7–36) amide by Ectopeptidases in RINm5F Cells , 1997, Peptides.

[20]  M. Humphrey,et al.  Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. , 1997, Xenobiotica; the fate of foreign compounds in biological systems.

[21]  J. Levy,et al.  Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM , 1997, Diabetologia.

[22]  J. Holst,et al.  Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7–36 amide]) in patients with NIDDM , 1996, Diabetologia.

[23]  A. Hamsten,et al.  The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients , 1996, Diabetes Care.

[24]  J. Holst,et al.  Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. , 1996, The American journal of physiology.

[25]  J. Holst,et al.  Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects , 1995, Diabetes.

[26]  B. Göke,et al.  Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36) amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides , 1995, Regulatory Peptides.

[27]  R. Pederson,et al.  Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. , 1995, Endocrinology.

[28]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[29]  L. B. Knudsen,et al.  Structure-activity studies of glucagon-like peptide-1. , 1994, The Journal of biological chemistry.

[30]  V. Marks,et al.  Glucagon-like peptide-1 (7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns. , 1993, The Journal of endocrinology.

[31]  B. Gallwitz,et al.  Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. , 1993, European journal of biochemistry.

[32]  J. Holst,et al.  Biological Effects and Metabolic Rates of Glucagonlike Peptide-1 7–36 Amide and Glucagonlike Peptide-1 7–37 in Healthy Subjects Are Indistinguishable , 1993, Diabetes.

[33]  J. Habener,et al.  Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37) , 1993, Nature.

[34]  B. Thorens.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Buckley.  Analysis of the degradation of insulinotropin [GLP-1(7–37)] in human plasma and production of degradation resistant analogs , 1992, Regulatory Peptides.

[36]  J. Habener,et al.  Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells. , 1992, Endocrinology.

[37]  G. Weir,et al.  Glucagonlike Peptide I (7–37) Actions on Endocrine Pancreas , 1989, Diabetes.

[38]  J. Holst,et al.  Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. , 1988, Endocrinology.

[39]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[40]  J. Holst,et al.  Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. , 1986, Endocrinology.

[41]  L. Orci,et al.  Preproglucagon gene expression in pancreas and intestine diversifies at the level of post-translational processing. , 1986, The Journal of biological chemistry.

[42]  N. Gee,et al.  An immunoradiometric assay for endopeptidase-24.11 shows it to be a widely distributed enzyme in pig tissues. , 1985, The Biochemical journal.